 Secured National Medicare Reimbursement for DetermaRxTM Starting August 2020 with Final Medicare LCD from Palmetto GBA and Noridian Healthcare SolutionsInternational Distribution with ProGenetics Expands Global Availability of DetermaRx to Israel in Addition to India, the Middle East and Africa Rapid Growth of DetermaRxTM Physician Adoption and Testing Volume Translating into Revenue DetermaDxTM Development Program Discontinuation Expected to Deliver Approximately 3 million in Annualized SavingsConference Call Today, July 29, at 4:30 PM EDTIRVINE, Calif., July 29, 2020 GLOBE NEWSWIRE -- Oncocyte Corporation NYSE American: OCX, a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today reported financial and operating results for the second quarter ended June 30, 2020, and provided a corporate update. Oncocyte is a much stronger company today than when I stepped into the CEO role a year ago with two acquisitions that de-risked our product portfolio by adding two proprietary, well validated and published tests to our menu, said Ron Andrews, Chief Executive Officer of Oncocyte. The second quarter proved to be an important chapter in the evolution of Oncocyte as we continue to gain momentum with our two commercial products with multiple important milestones for DetermaRxTM, which include securing national Medicare payment, revenue generation with reimbursements from multiple payers, a solid increase in physician adoption, increased testing volume with now well over 100 patients tested, and global distribution in Israel, India, the Middle East and Africa. In addition, with our compelling clinical data, the final LCD from Noridian established a new class of predictive tests for Medicare coverage in NSCLC, with DetermaRx now positioned as the first and only test in this class. This is a momentous accomplishment that establishes Oncocyte as a true pioneer in the advancement of molecular diagnostics for lung cancer.Mr. Andrews continued, We also continue our progress with DetermaIOTM with data presented at ASCO that demonstrated the potential utility of DetermaIO for immunotherapy response prediction in triple negative breast cancer, the deadliest form of breast cancer. These data, combined with the lung cancer data presented at SITC in 2019, suggest that DetermaIO may have broad applicability in solid tumors regardless of tissue type, which could enable our access to the estimated 5 billion and rapidly growing molecular diagnostic market for both comprehensive profiling to identify patients likely to respond to immune therapy and identifying patients who may require combination therapy to attain full sustained responses. We are actively pursuing near-term opportunities in both pharma services and academia for immunotherapy trials as we advance toward our ultimate goal of clinical launch and use of DetermaIO. Our continued track record of consistent execution with DetermaRx and DetermaIO, combined with our growing pharma services lab opportunity which has secured over 1 million in pharma services contracts already this year, positions Oncocyte for rapid revenue growth as an innovative leader in molecular diagnostics for lung cancer, TNBC and potentially other solid tumors. Recent Corporate Highlights DetermaRx Announced final Medicare local coverage determination LCD from both Noridian Healthcare Solutions and Palmetto GBA securing national Medicare payment for DetermaRx starting in August 2020 Noridian Healthcare Solutions LCD established a new class of predictive tests for Medicare coverage, based on compelling DetermaRx clinical evidence Noridian Healthcare Solutions LCD positions DetermaRx as the first and only test in this class for early-stage non-small cell lung cancer Announced commercial availability in January and now have 47 sites onboarded, including a number of community healthcare systems where most early stage cancer is treated Rapid growth of DetermaRx physician adoption has resulted in over 100 patients tested, and a physician reorder rate of 60 Expanded international availability through a distribution agreement with ProGenetics Ltd, adding commercial availability of DetermaRx to Israel, which is complementary to the prior agreement with CORE Diagnostics for India, the Middle East and Africa Announced publication of new long-term follow up data for DetermaRx in the American Journal of Respiratory and Clinical Care Medicine demonstrating potential clinical utility and benefit to patients and payers through reduced post-surgery follow-up of lung cancer patients Continued successful physician engagement with both virtual and in-person activities with over 1,800 participants in online physician education programs Announced KOL webinar showcasing new data and real-world usage of DetermaRx featuring renowned lung cancer experts Dr. David Gandara and Dr. Johannes Kratz on July 30, 2020 DetermaIO Presented data at 2020 ASCO Virtual Meeting highlighting the potential utility of DetermaIO for immunotherapy response prediction in triple-negative breast cancer. In this study, DetermaIO outperformed standard of care PD-L1 testing in identifying responders to the FDA-approved checkpoint inhibitor atezulimab Announced KOL webinar featuring MD Anderson breast cancer medical oncologist, and triple negative study Principal Investigator, Dr. Naeto Ueno on August 19, 2020 Initiated an Investigator Sponsored Trial utilizing DetermaIO as the predictive biomarker for an FDA-approved checkpoint inhibitor in the early stage neoadjuvant setting Continued advancement of pharma services opportunities, including immunotherapy trials and the potential for development of companion diagnostics for lung cancer and other solid tumors Pharma Services Continued growth of pharma services offering with a full suite of molecular analyses including tissue and blood-based technologies, proprietary platforms such as DetermaIO and TNBCType Assay, as well as custom next-generation sequencing and PCR services including whole exome sequencing, RNA-seq and targeted mutation panels Closed over 1M in secured pharma services contracts With collaborators from MD Anderson Cancer Center, announced the peer-reviewed publication in PLOS One with data demonstrating the utility of the TNBCType Assay to inform triple-negative breast cancer drug development by identifying the most suitable cell lines to help biopharma and academic researchers develop new treatments Financial and Corporate In April, Oncocyte successfully completed a 10.7 million registered offering of common shares, priced at the market, directly with fundamentally driven, healthcare focused institutional investors.Second Quarter 2020 Financial HighlightsAt June 30, 2020, Oncocyte had cash, cash equivalents and marketable securities of 17.1 million as compared to 22.5 million at December 31, 2019. Prior to January 1, 2020, Oncocyte had no revenues. Oncocyte currently derives its revenues from pharma services generated by its wholly owned subsidiary, Insight Genetics, which was acquired on January 31, 2020, and from the cash basis receipts from the sale of its lung cancer test, DetermaRxTM, which was commercially launched in early 2020.Under U.S. accounting principles, Oncocyte will be able to recognize revenues for DetermaRxTM on an accrual basis of accounting once it has contracts for reimbursement from third-party payers or a history of experience of cash collections for the tests performed, or both. Until that time, Oncocyte expects to recognize revenue for DetermaRxTM tests performed on a cash basis. Accordingly, Oncocyte will incur and accrue cost of revenues and other operating expenses related to its diagnostic tests, including DetermaRxTM.Beginning on January 31, 2020, Oncocytes consolidated financial statements and results also include the results from its wholly owned subsidiary, Insight Genetics, which Oncocyte acquired on that date.For the second quarter ended June 30, 2020, Oncocyte reported a net loss of 9.1 million, or 0.14 per share, as compared to 5.4 million, or 0.10 per share, for the second quarter ended June 30, 2019.Operating losses, as reported, for the second quarter of 2020 were 8.8 million, an increase of 3.3 million from 5.5 million as compared to the second quarter of 2019; and operating losses, on an adjusted basis, were 6.9 million, an increase of 2.2 million from 4.7 million as compared to the second quarter of 2019.Oncocyte has provided a reconciliation between GAAP and non-GAAP operating losses in the financial tables, included with this earnings release, which it believes is helpful in understanding its ongoing operations.Revenues for the three and six months ended June 30, 2020 were 143,000 and 158,000, respectively, primarily generated from pharma services, as revenues from DetermaRx tests were recognized only when Oncocyte received cash payment for the test rather than on an accrual basis when the tests were performed.Cost of revenues for the three and six months ended June 30, 2020 were 0.4 million and 0.5 million, respectively, primarily incurred from performing the DetermaRx tests and pharma services.Research and development expenses for second quarter of 2020 were 3.2 million as compared to 1.5 million for the same period in 2019, an increase of 1.7 million primarily attributable to personnel, outside services and laboratory related expenses for Clinical Validation activities of DetermaDx. General and administrative expenses for the second quarter of 2020 were 3.8 million, as compared to 3.6 million for the same period in 2019, which remained relatively unchanged from the prior year comparative period. 